Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a biopharmaceutical company that regularly issues news about its royalty portfolio, technology platforms and capital deployment. The company describes its model as enabling the clinical development of high‑value medicines by providing financing, licensing its technologies, or both, and this approach is reflected in its press releases and investor communications.
News about Ligand often covers financial results and guidance, including updates on total core revenue, royalty revenue, Captisol sales, contract revenue and non‑GAAP measures such as core adjusted earnings per diluted share. The company’s announcements highlight how royalty revenue from partnered products such as Filspari, Ohtuvayre, Capvaxive, Qarziba and Zelsuvmi contributes to its outlook, as well as how deployable capital and new royalty investments are expected to influence long‑term royalty receipts.
Investors following LGND news will also see updates on Ligand’s technology platforms and partner programs. Releases describe Captisol‑enabled approvals like Lasix ONYU, developments in programs such as Qtorin rapamycin, and clinical or regulatory milestones reported by partners that may affect Ligand’s royalty streams. In addition, the company reports on financing transactions, including convertible senior notes offerings and amendments to its credit agreement, which provide context on how Ligand funds royalty acquisitions and other strategic investments.
Corporate events such as Investor Day presentations and participation in healthcare and biopharma conferences are another recurring theme in Ligand’s news flow. These events typically feature discussions of strategy, investment activity, the royalty portfolio and long‑term financial outlook. For investors and observers, the LGND news page offers a centralized view of how Ligand’s royalty‑focused business model, technology licensing and capital allocation decisions evolve over time.
Ligand Pharmaceuticals (Nasdaq: LGND) announced its participation in two upcoming investor conferences in September 2025. CEO Todd Davis and CFO Tavo Espinoza will attend the Citi 20th Annual BioPharma Conference in Boston on September 3, participating in a fireside chat at 11:15 a.m. ET. The management team will also present at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9 at 1:00 p.m. ET.
During both conferences, management will be available for one-on-one meetings with investors and attendees through their respective conference representatives.
Ligand Pharmaceuticals (Nasdaq: LGND) has successfully completed its offering of 0.75% convertible senior notes due 2030, raising a total principal amount of $460.0 million. The company generated net proceeds of approximately $445.1 million after deducting fees and expenses.
The company allocated $45.9 million for convertible note hedge transactions and used $15.0 million to repurchase 102,034 shares at $147.01 per share. To manage potential dilution, Ligand entered into warrant transactions with a strike price of $294.02 per share, representing a 100% premium over the last reported share price.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced the pricing of $400 million convertible senior notes due 2030 in a private placement to qualified institutional buyers. The notes will carry a 0.75% annual interest rate, payable semiannually, with an initial conversion price of $194.79 per share, representing a 32.5% premium over the current stock price.
The company expects net proceeds of $386.9 million (or $445.1 million if the initial purchasers exercise their option). Ligand will use $39.9 million for convertible note hedge transactions, $15.0 million to repurchase 102,034 shares of common stock, and the remainder for general corporate purposes. The notes include provisions for conversion, redemption, and repurchase under specific conditions.
Ligand Pharmaceuticals (Nasdaq: LGND) announced plans to offer $400 million of convertible senior notes due 2030 in a private placement to qualified institutional buyers. The company will also grant initial purchasers a 13-day option to buy up to $60 million in additional notes.
The notes will be senior unsecured obligations with semiannual interest payments starting April 1, 2026. Upon conversion, Ligand will pay cash up to the principal amount and may settle the remainder in cash, stock, or a combination. The company plans to use the proceeds for convertible note hedge transactions, up to $30 million for share repurchases, and general corporate purposes including potential business investments.
To manage dilution, Ligand will enter into convertible note hedge and warrant transactions with option counterparties, though the warrant transactions could have a dilutive effect if the stock price exceeds the warrant strike price.
Ligand Pharmaceuticals (Nasdaq: LGND) reported strong Q2 2025 financial results and raised its full-year guidance. Total revenue reached $47.6 million, up 15% year-over-year, driven by a 57% increase in royalty revenue to $36.4 million. The company raised its 2025 guidance, now expecting total revenue of $200-225 million and adjusted EPS of $6.70-7.00.
Key highlights include the completion of the Pelthos Therapeutics merger, a $40 million strategic investment in Orchestra BioMed, and the commercial launch of Zelsuvmi. The company maintains a strong financial position with $245 million in cash and investments, including $26.5 million in Viking Therapeutics stock.
Ligand Pharmaceuticals (NASDAQ:LGND) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025. The company will host a conference call and webcast at 8:30 AM ET to discuss the quarterly performance and provide a business update.
Investors can access the call via phone at (800) 715-9871 (U.S. & Canada) or (646) 307-1963 (International) using Conference ID 3661098. A live webcast and replay will also be available through the company's website.
Ligand Pharmaceuticals (Nasdaq: LGND) announced that its partner Pelthos Therapeutics (NYSE American: PTHS) has launched ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum. The launch triggered a $5 million milestone payment to Ligand.
Following Pelthos' merger with Channel Therapeutics, Ligand now owns 56% of Pelthos. The agreement includes a 13% royalty on worldwide ZELSUVMI sales and potential for additional $5 million in commercial sales milestones.
Ligand Pharmaceuticals (Nasdaq: LGND) has completed its merger between subsidiary LNHC, Inc. and Channel Therapeutics' subsidiary CHRO Merger Sub Inc. The combined entity, Pelthos Therapeutics, will trade on NYSE American under ticker "PTHS" starting July 2, 2025.
Concurrent with the merger, Pelthos raised $50.1 million in equity capital, with $32 million from the Murchinson-led investor group and $18 million from Ligand. The company is preparing to launch ZELSUVMI™, an FDA-designated novel drug for Molluscum contagiosum infections, in July 2025. Ligand will receive a 13% royalty on worldwide ZELSUVMI sales.
ZELSUVMI is the first home-administered prescription treatment for molluscum, a condition affecting an estimated 16.7 million people in the US. Pelthos will also evaluate Channel's NaV 1.7 programs for various pain treatments.
Ligand Pharmaceuticals (LGND) has announced it will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis, along with senior management and board members, will participate in the ceremony to celebrate recent company milestones, including two value-creating transactions.
Davis highlighted Ligand's transformation into a profitable, infrastructure-light organization that focuses on acquiring and generating royalties from a diverse biopharmaceutical product portfolio. The company aims to continue building on its two-year momentum, supporting partner development of breakthrough medicines, and creating long-term shareholder value. The ceremony will be broadcast live at 9:15 a.m. Eastern Time.